TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas
TRIM21 may represent a therapeutic target for tumors, and inhibiting TRIM21 could be a potential strategy for tumor treatment.
Authors
- Hao Tang (ORCID: https://orcid.org/0000-0001-5401-7295)
- Xue Li (ORCID: https://orcid.org/0000-0003-0650-2194)
- Chuanbao Li
- Tao Zhang (ORCID: https://orcid.org/0000-0002-1772-0915)
- Yuting Dai (ORCID: https://orcid.org/0000-0001-8275-2115)
- Shaojian Lin (ORCID: https://orcid.org/0000-0002-7555-0520)
- Ning Huang (ORCID: https://orcid.org/0000-0002-7021-8705)
- Yanting Liu (ORCID: https://orcid.org/0000-0002-9591-3042)
- Fang Liu (ORCID: https://orcid.org/0000-0002-5379-8816)
- Zhe Wu (ORCID: https://orcid.org/0000-0002-1611-8228)
- Tianyi Han (ORCID: https://orcid.org/0000-0002-2441-9864)
- Xiaobin Wang
Institutions
- Henan University (CN)
- Shanghai Jiao Tong University (CN)
- Wenzhou Medical University (CN)
- Ruijin Hospital (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Institute of Immunology (HR)
- State Key Laboratory of Oncogene and Related Genes (CN)
- Shanghai Institute of Hematology (CN)
- First Affiliated Hospital of Henan University (CN)
- Shanghai Center for Brain Science and Brain-Inspired Technology (CN)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1093/neuonc/noae241
- Citations
- 13
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.65